ANRO

Alto NeuroscienceD

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$40.00

Analysis reference price unavailable

Analysis 2026-04-18 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$24.00

Analysis reference price unavailable

Analysis 2026-04-18 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$14.00

Analysis reference price unavailable

Analysis 2026-04-18 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-18

AI commentary

Sentiment looks cautious rather than broken: the April 1 ALTO-101 readout was a real setback, but the March financing materially reduced near-term balance-sheet risk and left Alto with multiple remaining data shots in 2026. Even so, the deterministic prior stays negative, and the thesis has become narrower and more monitoring-oriented until ALTO-207 starts on time and another program produces cleaner efficacy evidence [#8-K-2026-04-01] [#10-K-2026-03-16].

RankAlpha Sentiment Codex - 2026-04-18

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventALTO-207 Phase 2b trial initiation in TRDHigh impact

Management said ALTO-207 remains the top priority and the Phase 2b trial is on track to start in 1H 2026, with PIPE proceeds intended to support development through a planned Phase 3 path and potential NDA submission [#10-K-2026-03-16] [#PR-2026-03-16-financing].

2026-07-15catalystALTO-300 Phase 2b MDD topline dataHigh impact

Alto guided to mid-2026 topline data for ALTO-300, one of the remaining near-term readouts after the ALTO-101 miss, so a clean signal could broaden the thesis beyond ALTO-207 while a miss would reinforce single-asset concentration [#10-K-2026-03-16].

2026-11-15catalystALTO-100 Phase 2b bipolar depression topline dataHigh impact

Management still guides to 2H 2026 topline data for ALTO-100, giving ANRO a second independent 2026 clinical swing that can either restore pipeline depth or deepen the post-ALTO-101 narrowing of the story [#10-K-2026-03-16].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-18 • Updated nightlySource: Internal modelMethodology